Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Breast Cancer - Female
- Prostate Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: Single (Participant)Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
The overall goal is to study the effectiveness of SPECT imaging prostate cancer and breast cancer patients Using technetium-99m labeled RM26. Phase I of the study: Biodistribution of 99mTc-RM26 in patients with prostate cancer and breast cancer. The main objectives of the study: To evaluate the dist...
The overall goal is to study the effectiveness of SPECT imaging prostate cancer and breast cancer patients Using technetium-99m labeled RM26. Phase I of the study: Biodistribution of 99mTc-RM26 in patients with prostate cancer and breast cancer. The main objectives of the study: To evaluate the distribution of 99mTc-RM26 in normal tissues and tumors in patients with prostate cancer and breast cancer at different time intervals. To evaluate dosimetry of 99mTc-RM26 based on the pharmacokinetic parameters of the drug after a single intravenous administration. To study the safety of use and tolerability of the drug 99mTc-RM26 after a single intravenous administration in a diagnostic dosage. Additional research tasks: 1. To conduct a comparative analysis of the diagnostic information obtained in the visualization of prostate cancer and breast cancer by SPECT using 99mTc-RM26 with data obtained by CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) research of postoperative material. Methodology: Open-label, exploratory, single centre study. The subjects will receive a single injection of the labeled tracer.
Tracking Information
- NCT #
- NCT04746638
- Collaborators
- Uppsala University
- Investigators
- Principal Investigator: Vladimir I Chernov, MD,PhD Tomsk NRMC
Get Well Soon